FDA Approves First Liquid, Nonstimulant ADHD Treatment
The centrally acting alpha2-adrenergic agonist is approved for patients ≥6 years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The centrally acting alpha2-adrenergic agonist is approved for patients ≥6 years
Only registered members have full access to PracticeUpdate content.